Company Cyclerion Therapeutics, Inc.

Equities

CYCN

US23255M2044

Biotechnology & Medical Research

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-26 pm EDT			5-day change	1st Jan Change
2.93 ^USD	-3.62%		-16.29%	-12.54%

Mar. 05	Cyclerion Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Cyclerion Therapeutics, Inc. Appoints Regina Graul as President	CI

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company that focuses on developing treatments for serious diseases. The Companyâs portfolio includes novel soluble guanylate cyclase (sGC) stimulators, namely praliciguat and olinciguat, as well as multiple research stage molecules. Praliciguat is a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. Olinciguat is a vascular sGC stimulator that the Company intends to out-license for cardiovascular diseases. The Company operates through the human therapeutics segment. The Company is focused on identifying non-sGC stimulator assets within the central nervous system (CNS) therapeutic area to build a new portfolio. The Company is also evaluating other activities aimed at enhancing shareholder value, which potentially include collaborations, licenses, mergers, acquisitions and/or other targeted investments.

Number of employees: 1

Managers	Title	Age	Since
Regina Graul PSD	President	-	Dec. 03
Peter Hecht BRD	Director/Board Member	60	19-03-31

Members of the board	Title	Age	Since
Errol de Souza CHM	Chairman	70	21-04-25
Terry McGuire BRD	Director/Board Member	68	19-03-31
Peter Hecht BRD	Director/Board Member	60	19-03-31
Steven E. Hyman BRD	Director/Board Member	71	22-07-24
Michael Higgins BRD	Director/Board Member	61	Nov. 29
Dina Katabi BRD	Director/Board Member	-	Nov. 29

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	2,881,033	2,147,214 ( 74.53 %)	170,937 ( 5.933 %)	74.53 %
Stock B	0	351,037	0	0

Name	Equities	%	Valuation
Peter Hecht 13.93 %	377,457	13.93 %	1 M $
Slate Path Capital LP 13.21 %	357,880	13.21 %	1 M $
MFN Partners Management LP 6.253 %	169,460	6.253 %	542 272 $
Tyndall Management LLC 6.067 %	164,429	6.067 %	526 173 $
Fidelity Management & Research Co. LLC 6.009 %	162,849	6.009 %	521 117 $
Artal Group SA 5.127 %	138,955	5.127 %	444 656 $
American Endowment Foundation 4.909 %	133,027	4.909 %	425 686 $
Regina Graul 3.701 %	100,303	3.701 %	320 970 $
Terry McGuire 1.550 %	42,010	1.550 %	134 432 $
Geode Capital Management LLC 1.153 %	31,259	1.153 %	100 029 $

Cyclerion Therapeutics, Inc.

Riverview II 245 First Street

02142, Cambridge

http://www.cyclerion.com

address Cyclerion Therapeutics, Inc.(CYCN)

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
CYCLERION THERAPEUTICS, INC.	-12.54%	7.44M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+48.49%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research